These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9795299)

  • 1. [A national multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish Piperacillin-Tazobactam Group].
    Gobernado M; Bouza E; Perea E; Alvarez-Bravo J; García Rodríguez JA
    Rev Esp Quimioter; 1998 Jun; 11(2):139-46. PubMed ID: 9795299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam].
    García-Rodríguez JA; Trujillano I;
    Rev Esp Quimioter; 2002 Jun; 15(2):169-75. PubMed ID: 12582446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
    Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
    J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals.
    Verbist L; Dhoore P
    Acta Clin Belg; 1995; 50(5):274-81. PubMed ID: 8533527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
    Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
    Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
    Liebowitz LD; Klugman KP
    S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
    Gould IM; Milne K
    J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
    Mehtar S; Drabu YJ; Blakemore PH
    J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.